Atara Biotherapeutics Stock Fundamentals
| ATRA Stock | USD 6.62 0.30 4.34% |
Atara Biotherapeutics fundamentals help investors to digest information that contributes to Atara Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Atara Stock. The fundamental analysis module provides a way to measure Atara Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Atara Biotherapeutics stock.
Atara |
Atara Biotherapeutics Company Current Valuation Analysis
Atara Biotherapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Atara Biotherapeutics Current Valuation | 41.88 M |
Most of Atara Biotherapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atara Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Atara Biotherapeutics has a Current Valuation of 41.88 M. This is 99.71% lower than that of the Biotechnology sector and 99.1% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.75% higher than that of the company.
Atara Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Atara Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Atara Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atara Biotherapeutics competition to find correlations between indicators driving Atara Biotherapeutics's intrinsic value. More Info.Atara Biotherapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atara Biotherapeutics' earnings, one of the primary drivers of an investment's value.Atara Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atara Biotherapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atara Biotherapeutics could also be used in its relative valuation, which is a method of valuing Atara Biotherapeutics by comparing valuation metrics of similar companies.Atara Biotherapeutics is currently under evaluation in current valuation category among its peers.
Atara Fundamentals
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (0.66) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 41.88 M | ||||
| Shares Outstanding | 5.86 M | ||||
| Shares Owned By Insiders | 21.90 % | ||||
| Shares Owned By Institutions | 50.50 % | ||||
| Number Of Shares Shorted | 674.63 K | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 0.32 X | ||||
| Revenue | 128.94 M | ||||
| Gross Profit | (39.8 M) | ||||
| EBITDA | (75.75 M) | ||||
| Net Income | (85.4 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 29.91 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 5.28 X | ||||
| Book Value Per Share | (16.60) X | ||||
| Cash Flow From Operations | (68.72 M) | ||||
| Short Ratio | 5.64 X | ||||
| Earnings Per Share | (11.41) X | ||||
| Target Price | 12.25 | ||||
| Number Of Employees | 153 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 40.66 M | ||||
| Total Asset | 109.1 M | ||||
| Retained Earnings | (2.05 B) | ||||
| Working Capital | (69.68 M) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
| Net Asset | 109.1 M |
About Atara Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atara Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atara Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atara Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 578 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Atara Biotherapeutics Piotroski F Score and Atara Biotherapeutics Altman Z Score analysis. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.